Encodia, a US-based protein analysis technology spinout of Washington University in St Louis, closed a $75m series C round today co-led by Northpond Ventures and Deerfield Management.
GV, Alexandria Venture Investments and Nan Fung Life Sciences, respective units of internet technology conglomerate Alphabet, life sciences real estate developer Alexandria Real Estate Equities and property group Nan Fung, also participated in the round.
Arch Venture Partners, Biomatics Capital, Decheng Capital and Tao Capital filled out the investor line-up.
Encodia is commercialising large-scale protein analytics through a benchtop instrument. It  will use the investment to accelerate platform development.
Sharon Kedar of Northpond and Andrew ElBardissi of Deerfield have been appointed to Encodia’s board of directors.
Encodia does not appear to have disclosed any previous funding round, though it identified Arch Venture Partners, Biomatics Capital, Decheng Capital, Tao Capital Partners and Nan Fung Life Sciences as returning backers.
Find out more about Washington University in St Louis’ tech transfer operation in our podcast interview with Nichole Mercier.

US-based protein analysis technology developer Encodia closed a $75m series C round today featuring GV and Nan Fung Life Sciences, respective subsidiaries of internet technology conglomerate Alphabet and property development group Nan Fung.

The round was co-led by Northpond Ventures and Deerfield Management and included Alexandria Venture Investments, a vehicle for life sciences real estate investment trust Alexandria Real Estate Equities, as well as Arch Venture Partners, Biomatics Capital, Decheng Capital and Tao Capital.

Encodia is commercialising large-scale protein analytics through a benchtop instrument. The company, which was spun out of Washington University in St Louis, will use the investment to accelerate platform development.

Sharon Kedar of Northpond and Andrew ElBardissi of Deerfield have been appointed to Encodia’s board of directors in connection with the series C round.

Encodia does not appear to have disclosed any previous funding but identified Nan Fung Life Sciences, Arch Venture Partners, Biomatics Capital, Decheng Capital and Tao Capital as returning backers.

The original version of this article appeared on our sister site, Global University Venturing.